Table 2.

Compensatory vasodilation identification—vasodilatory and flow responses following a perfusion pressure compromise and their resulting level of significance

Subject	FVCRelax, min−1 ⋅ 100 mmHg−1	FVCRelax, P	FBF, ml/min	FBF, P
Placebo, n = 6
E	556 vs. 547	0.23	338 vs. 313	0.06
H	987 vs. 988	0.46	667 vs. 506	3.61E-03
O	630 vs. 640	0.56	366 vs. 329	0.10
R	520 vs. 532	0.60	290 vs. 207	9.88E-04
U	777 vs. 786	0.42	401 vs. 380	0.16
W	686 vs. 681	1.00	435 vs. 376	1.3E-03
Average ± SD	688 ± 166 vs. 697 ± 171	0.42	415 ± 131 vs. 353 ± 98*	0.03
Nitrate, n = 6
E	543 vs. 647	1.54E-05	350 vs. 353	0.87
H	758 vs. 898	1.35E-06	437 vs. 406	0.07
O	478 vs. 557	6.55E-05	316 vs. 324	0.25
R	431 vs. 604	3.40E-07	221 vs. 246	0.03
U	545 vs. 855	6.37E-05	308 vs. 335	5.33E-03
W	643 vs. 713	0.02	396 vs. 383	0.35
Average ± SD	568 ± 117 vs. 714 ± 139*	5.0E-03	338 ± 71 vs. 341 ± 55	0.69

Values presented for each participant are the means of the 3 trials. E-03–E-07, exponents to negative 3–7, respectively.

^*Statistical significant difference between reduced perfusion pressure and control perfusion pressure positions (P < 0.05).